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Background: Glucose-sensing neurons are located in several parts of the brain, but are
concentrated in the ventromedial nucleus of the hypothalamus (VMH). The importance of
these VMH neurons in glucose homeostasis is well-established, however, little is known
about their individual identity. In the present study, we identified a distinct glucose-sensing
population in the VMH and explored its place in the glucose-regulatory network.
Methods: Using patch-clamp electrophysiology on Pacap-cre::EYFP cells, we explored
the glucose-sensing ability of the pituitary adenylate cyclase-activating peptide (PACAP)
neurons both inside and outside the VMH. We also mapped the efferent projections of
these neurons using anterograde and retrograde tracing techniques. Finally, to test the
functionality of PACAPVMH in vivo, we used DREADD technology and measured systemic
responses.
Results: We demonstrate that PACAP neurons inside (PACAPVMH), but not outside
the VMH are intrinsically glucose inhibited (GI). Anatomical tracing techniques show that
PACAPVMH neurons project to several areas that can influence autonomic output. In vivo,
chemogenetic stimulation of these neurons inhibits insulin secretion leading to reduced
glucose tolerance, implicating their role in systemic glucose regulation.
Conclusion: These findings are important as they identify, for the first time, a specific
VMH neuronal population involved in glucose homeostasis. Identifying the different
glucose-sensing populations in the VMH will help piece together the different arms of
glucose regulation providing vital information regarding central responses to glucose
metabolic disorders including hypoglycaemia.
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INTRODUCTION
Glucose is the primary source of energy for the brain, so it is not surprising that several redundant
neural pathways are involved in the detection and tight regulation of this nutrient. Rapid changes in
glucose are detected by specialized glucose-sensing neurons which are distributed through different
parts of the brain. However, the densest concentration of glucose-sensing neurons is found in the
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ventromedial hypothalamus and, specifically in the ventromedial
nucleus (VMH), though little is known about their identity.
A specific role for the VMH in glucoregulation has been
described in classic rat experiments (1–3) and confirmed, more
recently, by using steroidogenic factor (SF-1) to selectively target
this nucleus in the mouse. The deletion of vesicular protein,
vGLUT2, in SF-1 neurons produces a marked defect in glucagon
secretion in response to fasting or hypoglycaemia (4), while the
chemogenetic or electromagnetic activation of SF-1 neurons, as
well as optogenetic activation of projections both to and from the
VMH cause hyperglycaemia (5–7).
The VMH is a complex structure containing many different
cell phenotypes, and work in the rat has identified a range
of neuronal responses to the application of glucose (8).
Approximately, 14% of rat VMH neurons are inherently
sensitive to increased glucose and respond with an increase in
electrical activity. These are termed glucose excited (GE) and
are thought to depend on glucose metabolism and inhibition
of an ATP-sensitive potassium channel for their intrinsic
sensing ability (8, 9). A much smaller subset (about 3% of
VMH neurons in the rat) reduce their firing in response to
glucose and are termed glucose inhibited (GI). Inherent GI
neurons in the VMH are dependent on an AMP-activated
protein kinase which triggers the production of nitric oxide
by the synthetic enzyme (NOS) which may, in turn, reduce
a membrane chloride conductance (8–11). Importantly,
14% of VMH neurons are also depolarized by reduced
glucose, but this is dependent on synaptic transmission.
Thus, these have been termed presynaptically excited by
decreased glucose (PED), but it is not clear whether their
synaptic drive comes from within or from outside the
VMH (or perhaps both). Another 19% of VMH neurons
respond to changes in glucose much higher than normally
experienced in vivo, and so the physiological relevance
of these to glucoregulation is debateable (8). Neurons
that project information from the VMH may or may not
themselves be intrinsically glucose sensing; they may respond
in opposing directions to changes in glucose; and, perhaps
two thirds of VMH neurons may have no direct role in
affecting glucose. Therefore, manipulation of a mixed SF-1
population is likely to produce a complex, “compound”
effect.
We have shown previously that a population of VMH
neurons co-localize SF-1 and pituitary adenylate cyclase-
activating peptide (PACAP), and that the expression of the
latter is sensitive to energy status (12). Also, work done by
Kalsbeek and colleagues has shown that PACAP from an
unknown source, acting through pre-autonomic neurons in
the hypothalamic paraventricular nucleus (PVH) can initiate
endogenous glucose production (13). In the current paper, we
demonstrate that PACAPVMH neurons are GI, and project to
different regions of the brain, including the PVH, thought to
be involved in the response to hypoglycaemia. Furthermore,
selective chemogenetic activation of PACAPVMH neurons can
inhibit insulin secretion and increase circulating glucose. This is
the first demonstration of a single, defined population of VMH
glucose-sensing neuron.
MATERIALS AND METHODS
Animals
All experiments were performed in accordance with the UK
Animals (Scientific Procedures) Act 1986, and approved by the
University of Manchester Animal Welfare and Ethics Review
Board. Pacap-IRES-cre (Pacap-cre) mice (kind gift from Prof.
Brad Lowell, Harvard Medical School, USA and Dr Michael
Krashes, National Institute of Health, USA) were generated and
described elsewhere (14). Pacap-cre mice were used for in vivo
physiological studies or crossed with a Rosa26-EYFP reporter line
(15) to generate Pacap-cre::EYFP mice for electrophysiological
recordings. C57BL/6J mice were obtained from Envigo, UK. All
mice were housed in groups of 2–5 with ad libitum access to
chow (Special Diet Services, Witham, UK) and water. They were
maintained on a 12 h light/dark cycle, at 22±1◦C and 45±10%
humidity. Electrophysiological recordings were carried out on
slices prepared from 6 to 8 week-old male or female mice, and
in vivo studies were performed on 8–12 week-old male mice.
Electrophysiological Recordings
Brain Slice Preparation
After sacrificing the animal, brain tissue was extracted and
placed in ice-cold, pre-gassed (with 95% O2 and 5% CO2),
artificial cerebrospinal fluid (CSF) containing 95mM NaCl,
1.8mM KCl, 1.2mM KH2PO4, 7mM MgSO4, 26mM NaHCO3,
15mM glucose, 50mM sucrose, 0.5mM CaCl2, and 0.005 mg/L
phenol red. 250µm thick coronal slices were cut using a 7000smz
vibrating microtome (Campden Instruments, Loughborough,
UK) and maintained in artificial CSF for at least 2 h at room
temperature before recording.
Whole-Cell Patch-Clamp Recording
Prior to recording, the slice containing the VMH was transferred
into a recording solution containing 127mM NaCl, 1.8mM KCl,
1.2mM KH2PO4, 1.3mM MgSO4, 26mM NaHCO3, 2.5mM
glucose, and 0.005 mg/L phenol red. Patch pipettes were
filled with 130mM K-gluconate, 10mM KCl, 2mM MgCl2,
10mM HEPES, 0.5mM EGTA, 2mM K2ATP, 0.5mM NaGTP
(pipette resistance 7). PACAP cells were visualized using a
fluorescent microscope (Olympus BX50WI, Japan). Current-
clamp recordings were amplified using AXOCLAMP-2A (Axon
Instruments, CA, USA) and acquired via a CED 1401 mk1 A/D
interface, controlled by Spike2 software (version 6, Cambridge
Electronic Design Limited, Cambridge, UK). Data analysis was
carried out using Spike2 software and plotted using Prism
(version 7, GraphPad Software, La Jolla California USA). Data
are represented as mean ± SEM. Firing frequency is normalized
against baseline firing frequency.
Applications
Recordings were allowed to stabilize at 2.5mM glucose for
at least 5min after which 1mM glucose was applied to
the bath. Following application, the solution was once again
changed to 2.5mM during the wash-out period. To measure
intrinsic activity, 1µM tetrodotoxin (TTX) (Cat. No.1069, Tocris
Biosciences, Bristol, UK) in 2.5mM glucose was applied to the
bath followed by a 1µM TTX in 1mM glucose for 3 to 5min.
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100 nM cholecystokinin (CCK-8S, Tocris Biosciences, Bristol,
UK) was also applied in 2.5mM glucose.
Surgery
The designer receptors exclusively activated by designer drugs
(DREADDs) were delivered by the adeno-associated viruses,
AAV8/hSyn-DIO-hM3D(Gq) tagged with mCherry (5.9 × 1012
vg/mL) or AAV2/hSyn-DIO-hM4D(Gi) tagged with mCherry
(5.60 × 1012 vg/mL; both Virus Vector Core, University of
North Carolina). The cre-dependent, AAV-DIO-synaptophysin-
mCherry (3 × 10 12 vg/mL) (kindly gifted by Dr Martin
Myers, University of Michigan, USA) used for anatomical
tracing has been described previously (6). Red-fluorescent
microspheres (0.04µm, Cat. No. F8793, Life Technologies, UK)
were used to confirm the targets identified via AAV-DIO-
synaptophysin-mCherry tracing. Pacap-cre::EYFP mice were
anesthetized using isoflurane and placed in a stereotaxic frame
(Kopf Instruments, Tujunga, CA, USA). The skull was exposed
using a small incision followed by craniotomy. Viruses or
tracers were delivered (unilaterally for tracing and bilaterally for
chemogenetic manipulation using DREADDs) through a pulled
glass micropipette controlled by a nanoinjector (Nanoinject
II Auto-Nanoliter Injector, Drummond Scientific Company,
Pennsylvania, USA) using co-ordinates based on the Mouse
Brain Atlas (16); VMH, AP −1.1mm, ML ±0.5mm, DV
−6.0mm; aBNST, AP +0.5mm, ML ±0.6mm, DV −4.7mm;
PVH, AP −0.9mm, ML ±0.2mm, DV −5.4mm; PVT, AP
−0.46mm, ML±0.05mm, DV −3.45mm; LH, AP −1.3mm,
ML ± 1.3mm, DV −5.2mm; PAG, AP −3.08mm, ML
±0.15mm, DV −3.5mm. Mice injected with viruses or
retrobeads were left in their home cages for 2 weeks to allow
for cell transduction and/or axonal transport. They were handled
daily for at least 1 week before any in vivo manipulations were
carried out.
DREADD Experiments
To understand the effect of activating the cell bodies, PACAPVMH
neurons were transfected with the stimulatory DREADD,
AAV8/hSyn-DIO-hM3D(Gq). Two weeks later, baseline blood
glucose was measured followed by a 1 mg/kg clozapine-N-
oxide (CNO) (Cat. No. 6329, Tocris Biosciences, Bristol, UK)
injection intraperitoneal (i.p.). CNO for injection was freshly
prepared on the day of the test in sterile saline. Glucose levels
were monitored at 30, 60, 90 and 120min after CNO using
a glucometer (CodeFree, SD Biosenser, Korea). In a separate
experiment, serum samples were collected 30min after saline
or CNO injections and quantified using Ultra Sensitive Mouse
Insulin ELISA kit (90080, Crystal Chem, IL, USA) and Mercodia
Glucagon ELISA kit-10 µl (10-1281-01, Uppsala, Sweden).
For the intraperitoneal glucose tolerance test (IPGTT), mice
transfected with hM3Dq, were fasted from 9 a.m. to 1 p.m.
on the test days. Following the protocol of Steculorum et al.
(17), mice were given two injections of CNO separated by 1 h.
Immediately after the second injection, baseline glucose was
measured and themice were given 2 g/kg of glucose (i.p.). Further
glucose measurements were made at 15, 30, 60, 90, and 120min
after CNO or control saline injections. To demonstrate that
CNO injection was not producing an effect by itself, wild-type
C57BL/6J mice were handled for 2 weeks before carrying out
the same IPGTT protocol. To carry out the insulin tolerance test
(ITT), mice transfected with the inhibitory DREADD (hM4Di),
were fasted from 9 a.m. until 1 p.m. on the test days. Baseline
blood glucose was measured followed by a 1 mg/kg CNO
injection (i.p.). 30min after the first injection, the mice were
given subcutaneous injections of 1.75 U/kg Insulin (Humulin,
Eli Lilly and Company Ltd). Further glucose measurements were
made at 30, 60, 90, and 120min after insulin injections. Data were
analyzed and plotted using GraphPad Prism Version 7.
Dual-Label Immunohistochemistry
Mice were anesthetized with isoflurane and perfused
transcardially with 0.9% NaCl containing heparin followed
by 4% paraformaldehyde in phosphate buffer (PB). The brain
was removed into the same fixative overnight followed by
30% sucrose solution for another 3 days. 30 µM coronal brain
sections were cut using a freezing sledge microtome and dual
labeling was performed as described previously (18). Briefly,
free-floating sections were permeabilized in Tris-PB (0.2%
Triton X-100 (Sigma Aldrich, UK) in 0.1M PB) followed
by an overnight incubation with primary antibodies: 1:1,000
anti-GFP (ab13970, Abcam, Cambridge, UK) for EYFP, 1:1,000
anti-nitric oxide synthase 1 (AB5380, Merck Millipore, UK),
1:2,500 anti-DsRed (632496, Clontech Laboratories, Inc, CA,
USA) for mCherry staining and 1:500 cFos (sc-52, Santa Cruz
Biotechnology, Dallas, TX, USA). Primary antibodies were
visualized using 1:1,000 Alexa fluor secondary antibodies
A11039 and A11037, Invitrogen. For cFos staining, signal was
amplified using Biotin-SP-conjugated secondary antibody (711-
065-152, Jackson ImmunoResearch Laboratories, Pennsylvania,
USA), and Alexa tagged streptavidin (016-540-084, Jackson
ImmunoResearch Laboratories, Pennsylvania, USA). Images
were taken using an Axio Imager.D2 upright fluorescent
microscope (Zeiss, Sweden) and micrographs captured using
a Coolsnap HQ2 camera (Photometrics, Tucson, AZ, USA)
via Micromanager software v1.4.23 (https://micro-manager.
org/). The images were further processed in ImageJ (19) and
merged in Corel Paint Shop Pro Photo X2 (Corel, Ottawa,
Canada).
Statistical Analysis
All data sets were analyzed and plotted as mean±standard error
of mean using GraphPad Prism version 7. Electrophysiological
recordings were analyzed using either one-way ANOVAor paired
t-tests and significance was set at p-value< 0.05. IPGTT and ITT
data were analyzed using repeated measure two-way ANOVA
with Sidak post-hoc comparisons. Hormone data changes were
analyzed using unpaired t-tests.
RESULTS
Visualization of sections from Pacap-cre::EYFP mice
confirmed that PACAP-containing neurons have a widespread
distribution in the forebrain (14) including in many
nuclei of the hypothalamus (Figure 1A). Using dual-label
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FIGURE 1 | PACAP neurons inside, but not outside the VMH are GI: analysis of PACAP neurons from Pacap-cre::EYFP mice. (A) Representative coronal brain section
from a Pacap-cre::EYFP mouse. The accompanying sketch summarizes the distribution of glucose-responsive and non-responsive neurons (PACAP and
non-.PACAP) in the ventromedial hypothalamus. (B) Representative image (inset higher magnification) of dual-label immunohistochemistry showing co-localization of
nNOS labeling with PACAPVMH. (C) Whole-cell patch-clamp recordings showing the response to a change in glucose (2.5mM to 1mM) on PACAP neurons inside (i)
and outside (ii) the VMH. (D) (i) Quantitative (increase in baseline firing frequency; paired t-test, *p < 0.05, n = 8) and (ii) qualitative analysis of PACAPVMH neuron
response to low glucose. (E) The neurons respond to low glucose with depolarization in the presence of TTX.
immunohistochemistry, we observed that PACAP-EYFP is
expressed in 15% of neurons staining for neuronal nitric oxide
synthase 1 (nNOS) within the VMH (Figure 1B). Whole-
cell patch-clamp electrophysiology demonstrated that 13/18
PACAPVMH neurons responded to a decrease in glucose (2.5
mM to 1mM) with an increase in firing rate (average change
from 2.5mM 0.70±0.2Hz to 1mM 1.3±0.2Hz), which was
reversed when 2.5mM glucose was reinstated (Figures 1C,D).
Four PACAPVMH neurons did not respond, and one showed a
slight decrease in firing rate. By contrast, 2/10 PACAP neurons
outside the VMH, in the area immediately surrounding the
nucleus, responded to glucose. PACAPVMH neurons were
tested in the presence of TTX to block action potentials. 5/6
neurons still responded to low glucose with depolarization
(Figure 1E and Figure S1), demonstrating that they are
intrinsically GI. Also, since the VMH receives input from
other glucose-sensing regions of the brain, including from
cholecystokinin (CCK)-containing neurons in the brainstem
parabrachial nucleus (5, 6), we wished to test if PACAPVMH
neurons could integrate such information 19/21 PACAPVMH
neurons responded to CCK with a transient depolarization
of their membrane potential and an increase in firing rate
(Figure 2).
Next we injected Pacap-cre mice with a cre-dependent,
AAV-DIO-synaptophysin-mCherry virus (6) unilaterally into
the VMH. Synaptophysin is a synaptic vesicle protein and,
thus, the mCherry-tagged transgenic protein is transported
to the terminals of PACAPVMH neurons and can be used
as an anterograde neuroanatomical tracer. Sections from the
whole brain were cut and analyzed for synaptophysin-mCherry
staining. Cell bodies were labeled in the injected VMH, as were
synaptic boutons, suggesting that PACAP neurons terminate
within the nucleus itself. There was sparse staining in many parts
of the hypothalamus, but very strong staining was observed in
the paraventricular nucleus (PVH) and the lateral hypothalamic
(LH) area (Figure 3). The PVH, in particular, had dense boutons
ipsilateral to the injection site though terminals were clearly
visible on both the ipsilateral and contralateral sides. Three
other regions of the brain demonstrated strong terminal staining:
the anterior part of the bed nucleus of the stria terminalis
(aBNST), the paraventricular nucleus of the thalamus (PVT)
and throughout the periaqueductal gray (PAG). To confirm
direct projections, each of the five main target regions were
injected with red-fluorescent, latex microbeads unilaterally in
separate Pacap-cre::EYFP mice. These microbeads are taken
up by nerve terminals in the vicinity of the injection site,
and transported retrogradely to the cell bodies of origin.
In this way, we confirmed that PACAPVMH neurons project
directly to the PVH, LH, aBNST, PVT, and ventrolateral PAG
(Figure S2).
From the results so far, PACAPVMH neurons are a relatively
small population of cells in the VMH, which project to regions
of the brain that may affect glucose homeostasis (see section
Discussion). Currently, we do not know if individual neurons
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FIGURE 2 | Activation of PACAPVMH neurons by local administration of CCK: (A) Whole-cell patch-clamp recording of a PACAPVMH neuron following CCK
application (100 nM in 2.5mM glucose). B (i) CCK application transiently increased firing frequency compared with baseline (*p < 0.05, one-way ANOVA with repeated
measures, n = 9 cells from 7 mice). B (ii) A concomitant increase in membrane potential following CCK application (*p < 0.05, one-way ANOVA with repeated
measures, n = 8 from 7 mice).
FIGURE 3 | Efferent anatomical projections of PACAPVMH neurons: (A) Summary of efferent connections in Pacap-cre::EYFP mice using expression of AAV-driven
synaptophysin tagged with mCherry. (B) Fluorescent micrograph showing PACAPVMN transfected with synaptophysin virus. (C) Fiber staining showing projections to
the anterior BNST (aBNST), paraventricular hypothalamic nucleus (PVH), paraventricular thalamic area (PVT), lateral hypothalamus (LH) and periaqueductal gray (PAG)
were observed. Inset higher magnification show axonal terminals to the above mentioned area.
project to one or several of these target areas. Therefore, we
aimed to activate as many PACAPVMH neuronal cell bodies
in vivo as possible using a chemogenetic approach. GI cells
have been implicated in the counter-regulatory response to
hypoglycaemia and, therefore, their activation is predicted
to increase circulating glucose. In an initial experiment, the
cre-dependent DREADD, AAV8/hSyn-DIO-hM3D(Gq), was
injected bilaterally in the VMH of Pacap-cre mice. Only animals
with bilateral transduction of PACAPVMH neurons (Figure S3)
were included in analysis, and CNO caused a delayed increase
in baseline glucose levels (Figure S4). To confirm neuronal
activation, later half the mice were given a further injection of
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CNO and perfused to allow immunohistochemistry for cFos.
This demonstrated a clear activation of PACAPVMH neurons
(Figure S5). We then repeated this experiment, but this time
measured circulating hormone levels. Importantly, a decrease
in plasma insulin compared with control mice was observed
following CNO injection, whereas glucagon levels were not
altered (Figure 4).
This suggested to us that the role of PACAP neurons in
glucose regulation may be via a hormonal response, likely
by inhibiting insulin release. To confirm this possibility, we
chose the IPGTT model, since it is a situation when the mice
secrete insulin in response to glucose administration. Also, in
this scenario GI neurons would normally be inhibited and
hypoglycaemia counter-regulatory hormones low. Control mice
given the IPGTT displayed the expected increase in circulating
glucose which peaked around 15min and returned to baseline
by 60min. Mice pre-injected with CNO demonstrated impaired
glucose tolerance, as predicted: there was a greater plasma glucose
excursion (Figure 5). However, since concerns have been raised
recently that CNO can, in certain circumstances, be broken down
to the active drug clozapine and have off-target effects of its
own (20–22), we carried out a control experiment in which
wild-type C57BL/6J mice were treated in the same way. In this
case, treating the mice with CNO did not affect the IPGTT
(Figure S6).
Lastly, we wished to confirm that PACAPVMH neurons are
not affecting glucagon secretion, for which an IPGTT cannot be
used since the hyperglycaemia itself would reduce this hormone.
Therefore, instead, we carried out an insulin tolerance test
(ITT) while inhibiting PACAPVMH neurons with AAV2/hSyn-
DIO-hM4D(Gi). Further supporting our earlier results, no
differences in circulating glucose or glucagon levels following
DREADD-induced inactivation were observed in a situation of
high circulating insulin (Figure S7).
DISCUSSION
A full understanding of how the brain maintains homeostasis
can only be gleaned once individual neurons underpinning a
mechanism have been identified. Our knowledge of the central
regulation of glucose has lagged behind that of other homeostatic
systems, such as those which control appetite, sleep or plasma
electrolytes, despite the fact that the main location of specialist,
glucose-sensing neurons has been known for over 50 years
(23). The VMH is a complex structure with many functions,
including in feeding, sexual, and aggressive behavior (7, 24–
26), but it also has the highest density of neurons which can
respond to small changes in ambient glucose. In fact, the VMH
experiences glucose levels much lower than those circulating
in the bloodstream [the physiological range experienced in
the healthy rodent probably lies between 0.15 and 2.5mM
(27, 28)]. This realization has led to the redefinition of true,
inherent glucose sensing, but with the VMH still containing
the highest density of intrinsically sensitive GE and GI cells.
Despite this, the identity of any single population has remained
elusive. Meanwhile, direct evidence has been accumulating for
the existence of intrinsically sensitive neurons elsewhere in the
brain, including GE cells (for example, melanin-concentrating
hormone neurons in the LH) (29) and GI cells (for example,
orexin/hypocretin neurons in the LH) (29), glucose transporter
2 neurons in the PVT (30) and leptin-receptive CCK neurons in
the parabrachial nucleus (6, 31).
Attempts have been made to define populations of VMH
neuron by their expression of proteins hypothesized to
FIGURE 4 | Activation of PACAPVMH neurons causes inhibition of insulin release: (A) Schematic sketch representing intracranial, bilateral injection of cre-dependent
stimulatory DREADDs in Pacap-cre mice. (B) Change in glucose-sensitive hormones following CNO injections: (i) decrease in insulin (ii) no change in glucagon
response. Data are analyzed using unpaired t-test (*p < 0.05).
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FIGURE 5 | Activation of PACAPVMH neurons causes an increase in glucose
during a glucose tolerance test (IPGTT): Pacap-cre mice were given
intracranial, bilateral injection of cre-dependent stimulatory DREADDs. (A)
Schematic sketch representing the protocol used for an IPGTT experiment.
(B) Two weeks post-surgery, mice were injected with either saline or CNO
followed by an IPGTT. Data are analyzed using two-way ANOVA with repeated
measures (*p < 0.05, **p < 0.01 and ***p < 0.001).
distinguish the ability to sense glucose. For example, the low-
affinity glucokinase and the KATP channel, which are key to the
glucose sensitivity of pancreatic β cells, have been implicated in
glucose sensing by neurons (32, 33). Indeed, the electromagnetic
or optogenetic activation of glucokinase-expressing cells in an
extended region of the ventromedial hypothalamus (including
the arcuate, ventromedial, and dorsomedial nuclei) will increase
circulating glucose (7). However, at best, these markers are found
in mixed populations of GE, GI, and non-glucose sensing cells
(32). Perhaps the best distinguishing marker in the VMH is
nNOS, which appears to be a molecular requirement for GI,
but not GE cells in this nucleus (11, 34), though it is not
clear if nNOS is also found in non-sensing neurons within
the VMH, as it clearly is outside the nucleus. Here we have
identified what appears to be a single, identifiable population of
glucose-sensing VMH cell. Dual-labeling indicates that PACAP
neurons in the VMH are one type of nNOS-positive GI cell.
Recent publications have postulated that GI CCK neurons in the
brainstem parabrachial nucleus send a monosynaptic connection
to the VMH which can engage counter-regulatory mechanisms
in response to hypoglycaemia (5, 6, 31). And, since all CCK input
to the VMH is believed to come from the parabrachial nucleus
(35), it is relevant that PACAPVMH neurons increase their activity
in response to CCK and, thus, are responsive both directly and
indirectly to hypoglycaemic stimuli.
VMH neurons are most sensitive to changes in glucose at the
lower end of the range and the responses are activated following
rapid, rather than to slow-onset hypoglycaemia (36). Thus, it
is likely that PACAPVMH neurons are involved in protecting
the brain against glucoprivation rather than the maintenance of
normal, inter-meal glucose levels. Here, we have demonstrated
that PACAPVMH neurons project densely within the VMH,
and externally to the PVH, LH, aBNST, PVT, and PAG, which
compares with the general projection profile noted for the mixed
population of SF-1-positive neurons by Morton et al. (5). They
describe SF-1 projections to the PVH, aBNST, central amygdala
(CeA) and PAG. We might suggest that PACAPVMH neurons
can project to downstream effector regions directly, but also
indirectly, perhaps via a major population of SF-1-positive PED
neurons in the dorsomedial VMH. This is comparable to recently
described PACAP neurons in the central VMH which synapse
within the ventrolateral VMH, possibly connecting circadian
rhythmicity onto aggressive behaviors (26).
Although the optogenetic stimulation of all SF-1 neurons
together can increase circulating glucose (5), this is a compound
response since, by definition, SF-1 is expressed in multiple
populations. These populations can normally respond in
opposite directions to glucose, or have no role in normal
glucoregulation, but can produce additional unrecorded
behaviors, such as avoidance or aggression (25, 26) which may
or may not affect glucose levels indirectly. We now show that
chemogenetic stimulation of PACAPVMH cell bodies alone
is sufficient to increase circulating glucose in the setting of a
glucose-tolerance test, probably via inhibition of insulin release.
Morton et al. (5) found that optical stimulation of all SF-1 cell
bodies increased glucose in this situation, apparently by both
inhibiting glucose-induced insulin release and by causing the
secretion of the counter-regulatory hormones, glucagon and
corticosterone. Here, we found no effect on circulating glucagon.
It is possible that the compound glucose response to SF-1
cell stimulation is dominated by the output of PED neurons
located mainly in the dorsomedial VMH, which may be the most
responsive to optogenetic stimulation, or which may produce
the strongest downstream response. The issue of activating this
mixed population is further complicated by an independent
study which found that chemogenetic activation of all SF-1
neurons actually decreased glucose during a glucose tolerance
test, by increasing glucose uptake into skeletal muscle (37).These
discrepancies highlight the need to identify and manipulate
single-cell populations in the VMH.
Morton et al. (5) went on to show that optical stimulation of
SF-1 terminals in the aBNST, but not in the PVH, CeA, or PAG,
induced an increase in circulating glucose concomitant with
the secretion of glucagon and corticosterone, and the inhibition
of insulin. We have demonstrated significant projections from
PACAPVMH neurons to the aBNST and PVH, but also to the LH
and PVT. Since PACAPVMH neurons are intrinsically GI they
are almost certain to be a key element in glucose regulation.
However, because they are a relatively sparse population and
likely to influence effector sites both directly and indirectly
(through local VMH connections), it may make them difficult to
interrogate specifically using optogenetic stimulation of terminal
fields. Morton et al. (5) did report that optical stimulation of
SF-1 terminals in the PVH caused a non-significant increase in
corticosterone. Thus, the PACAPVMH→ PVH pathway is worth
further investigation, not least because Kalsbeek and colleagues
have previously shown that PACAP, of unknown source, can act
in the PVH to increase plasma glucose levels and endogenous
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glucose production (13). Likewise, direct PACAPVMH projections
to the LH are also interesting. The LH is the location of GI
orexin/hypocretin neurons which are also positioned to affect
many aspects of hypoglycaemia counter regulation, including
a potential role in a behavioral response leading to increased
feeding (38–40). Also, glucose transporter 2-containing neurons
in the PVT are glucose sensing and can initiate sucrose seeking
(30). Our identification of the first phenotypically-defined,
glucose-sensing neuron in the VMH, the key nucleus involved
in the responses to hypoglycaemia, will help us to piece together
the neuronal network involved in glucose homeostasis.
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Figure S1 | Changes in membrane potential following TTX application: a
significant increase in membrane potential in response to low glucose in the
presence of TTX was observed. Data are analyzed using paired t-test (∗p < 0.05),
n = 6.
Figure S2 | Confirmation of observed efferent PACAPVMH connections: efferent
connections of PACAPVMH neurons to the aBNST, PVH, LH, and PAG, previously
observed using AAV-driven synaptophysin, were confirmed here using retrograde
tracing. For each target region, the injection site is shown in the left panel and
retrobead-containing PACAPVMH neurons in the right panel.
Figure S3 | Bilateral transfection in VMH: only mice showing bilateral transfection
with the stimulatory DREADD, AAV8/hSyn-DIO-hM3D(Gq), were included in the
analysis.
Figure S4 | Changes in baseline glucose levels following activation of PACAPVMH
neurons: 8–10 week old, male mice were injected with saline or CNO (i.p.) and
changes in baseline glucose levels measured. A transient increase in baseline
glucose levels following CNO injections was observed in mice after CNO injection.
Figure S5 | cFos in PACAPVMH neurons using DREADD: cFos expression (green)
in PACAPVMH neurons following (A) (i) Saline or (ii) CNO injections. (B) A
significant increase in mCherry tagged neurons containing cFos was observed
following CNO injections, compared with controls. Data are analyzed using
unpaired t-test, ∗∗∗∗p < 0.0001.
Figure S6 | Effect of CNO in C57BL/6J: 8–10 weeks, male mice were injected
with either saline or CNO followed by an IPGTT. No difference in (A) (i) glucose
profiles and (ii) AUC was observed between the two groups. Two-way ANOVA
with repeated measure and unpaired t- test, n = 6 in each group.
Figure S7 | Inhibition of PACAPVMH neurons causes no change in glucose or
glucagon during an insulin tolerance test (ITT): (A) Silencing of PACAPVMH
neurons by CNO pretreatment did not change insulin-induced glucose response
compared with controls. Data are analyzed using two-way ANOVA with repeated
measure (∗∗∗∗p < 0.0001). (B) Glucagon levels were unchanged after CNO
injections compared with controls. Data are analyzed using unpaired t-test.
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